Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

被引：0

作者：

Fabrice Barlesi

Laure Deyme

Diane-Charlotte Imbs

Elissa Cousin

Mathieu Barbolosi

Sylvanie Bonnet

Pascale Tomasini

Laurent Greillier

Melissa Galloux

Albane Testot-Ferry

Annick Pelletier

Nicolas André

Joseph Ciccolini

Dominique Barbolosi

机构：

[1] Aix Marseille University,Marseille Early Phases Cancer Trials Center CLIP

[2] APHM,SMARTc Unit Centre de Recherche en Cancérologie de Marseille Inserm U1068

[3] Aix Marseille University,Department of Pharmacology Marseille

[4] Gustave Roussy Cancer Campus,undefined

[5] Aix Marseille University,undefined

[6] APHM,undefined

[7] Metronomics Global Health Initiative,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2022年 / 90卷

关键词：

Lung cancer; Mesothelioma; Mathematical modelling; Vinorelbine; Metronomic;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：149 / 160

页数：11

共 50 条

[41] Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial
Camerini, A.
Morabito, A.
Montanino, A.
Bernabe, R.
Grossi, F.
Ramlau, R.
Ciuleanu, T-E
Ceresoli, G-L
Pasello, G.
de Marinis, F.
Bosch-Barrera, J.
Laundreau, P.
Gautier, S.
Minh, C. Ta Thanh
Kowalski, D.
ESMO OPEN, 2021, 6 (02)
[42] Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma
Hutson, TE
Ganapathi, R
Elson, P
Mekhail, T
Olencki, T
Budd, GT
Bukowski, RM
INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 277 - 284
[43] The raltitrexed-vinorelbine combination:: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer
Ferrero, JM
Chamorey, E
Magné, N
Leccia, F
Largillier, R
Namer, M
Milano, G
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) : 459 - 464
[44] Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma
Thomas E. Hutson
Ram Ganapathi
Paul Elson
Tarek Mekhail
Thomas Olencki
G. Thomas Budd
Ronald M. Bukowski
Investigational New Drugs, 2004, 22 : 277 - 284
[45] PHASE I/II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER
TOUSSAINT, C
IZZO, J
SPIELMANN, M
MERLE, S
MAYLEVIN, F
ARMAND, JP
LACOMBE, D
TURSZ, T
SUNDERLAND, M
CHABOT, GG
CVITKOVIC, E
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2102 - 2112
[46] Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.
Berchuck, A
Secord, AA
Havrilesky, LJ
Wenham, R
Soper, JT
Clarke-Pearson, DL
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 487S - 487S
[47] Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer
Masters, GA
Hoffman, PC
Hsieh, AL
Drinkard, LC
Mick, R
Samuels, BL
Guaspari, A
Golomb, HM
Vokes, EE
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 884 - 892
[48] The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer
Jean-Marc Ferrero
Emmanuel Chamorey
Nicolas Magné
Frédéric Leccia
Rémy Largillier
Moïse Namer
Gérard Milano
Cancer Chemotherapy and Pharmacology, 2002, 50 : 459 - 464
[49] Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
Frenel, Jean-Sebastien
Mathiot, Laurent
Cropet, Claire
Borcoman, Edith
Hervieu, Alice
Coquan, Elodie
de la Motte Rouge, Thibault
Saada-Bouzid, Esma
Sabatier, Renaud
Lavaud, Pernelle
Jimenez, Marta
Legrand, Francois
Le Saux, Olivia
Charafe, Emmanuelle
Goncalves, Anthony
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
[50] Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy
Banna, Giuseppe L.
Camerini, Andrea
Bronte, Giuseppe
Anile, Giuseppe
Addeo, Alfredo
Rundo, Francesco
Zanghi, Guido
Lal, Rohit
Libra, Massimo
ANTICANCER RESEARCH, 2018, 38 (06) : 3689 - 3697

← 1 2 3 4 5 →